PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) came out with its full-year results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. Revenues came in at US$224m, in line with forecasts and the company reported a statutory loss of US$1.75 per share, roughly in line with expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for PROCEPT BioRobotics

Taking into account the latest results, the consensus forecast from PROCEPT BioRobotics' nine analysts is for revenues of US$321.9m in 2025. This reflects a huge 43% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 12% from last year to US$1.49. Before this earnings announcement, the analysts had been modelling revenues of US$314.1m and losses of US$1.32 per share in 2025. So it's pretty clear the analysts have mixed opinions on PROCEPT BioRobotics even after this update; although they upped their revenue numbers, it came at the cost of a notable increase in per-share losses.

It will come as no surprise that expanding losses caused the consensus price target to fall 8.7% to US$93.86with the analysts implicitly ranking ongoing losses as a greater concern than growing revenues. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on PROCEPT BioRobotics, with the most bullish analyst valuing it at US$105 and the most bearish at US$77.00 per share. This is a very narrow spread of estimates, implying either that PROCEPT BioRobotics is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that PROCEPT BioRobotics' revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 43% growth on an annualised basis. This is compared to a historical growth rate of 55% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 7.8% per year. So it's pretty clear that, while PROCEPT BioRobotics' revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at PROCEPT BioRobotics. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple PROCEPT BioRobotics analysts - going out to 2027, and you can see them free on our platform here.

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for PROCEPT BioRobotics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.